	US 11,904,021 B2
	Dual targeting and therapeutic nanoparticle for treating renal fibrosis
Chung Hang Jonathan Choi, Hong Kong (CN); Cecilia Ka Wing Chan, Hong Kong (CN); and Yun Wong James Lau, Hong Kong (CN)
Assigned to THE CHINESE UNIVERSITY OF HONG KONG, Hong Kong (CN)
Filed by The Chinese University of Hong Kong, Hong Kong (CN)
Filed on Oct. 22, 2021, as Appl. No. 17/452,041.
Claims priority of provisional application 63/104,262, filed on Oct. 22, 2020.
Prior Publication US 2022/0152220 A1, May 19, 2022
Int. Cl. A61K 47/69 (2017.01); A61K 33/242 (2019.01); A61K 33/38 (2006.01); A61K 33/26 (2006.01); A61P 13/12 (2006.01); A61K 33/243 (2019.01); A61K 47/54 (2017.01); A61K 9/51 (2006.01); A61K 33/24 (2019.01)

CPC A61K 47/6929 (2017.08) [A61K 9/5146 (2013.01); A61K 33/24 (2013.01); A61K 33/242 (2019.01); A61K 33/243 (2019.01); A61K 33/26 (2013.01); A61K 33/38 (2013.01); A61K 47/545 (2017.08); A61P 13/12 (2018.01)]

18 Claims

1. A dual function bionanomaterial for the treatment of kidney fibrosis comprising a nanoparticle comprising:

a metal core;

at least one polymer; and

at least 16 dual function targeting and therapeutic molecules, wherein the size of the dual function bionanomaterial is about 5.2 nm to about 10 nm in diameter, wherein the dual function bionanomaterial is folic acid, folate, dihydrofolate, tetrahydrofolate, 10-formyl, or 5-methyl substituted folate.